Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Farb

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Circulation|January 24, 2002
Morphological predictors of arterial remodeling in coronary atherosclerosisAllen P Burke, Frank D Kolodgie, Andrew Farb, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|June 9, 2009
Unusual cardiovascular manifestations of sarcoidosis, a report of three cases: coronary artery aneurysm with myocardial infarction, symptomatic mitral valvular disease, and sudden death from ruptured splenic arteryJoel H Barton, Fabio Tavora, Andrew Farb, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 22, 2004
Histology of in-stent restenosis in a transplanted heartPeter N Ruygrok, Andrew Farb, H Arthur Coverdale, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|March 30, 2016
New technology in electrophysiology: FDA process and perspectiveKimberly A Selzman, Mark Fellman, Andrew Farb, et al.
Circulation|June 26, 2002
Morphological predictors of restenosis after coronary stenting in humansAndrew Farb, Deena K Weber, Frank D Kolodgie, et al.
Circulation|March 12, 2003
Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findingsGiulio Guagliumi, Andrew Farb, Giuseppe Musumeci, et al.
Circulation|October 31, 2002
Oral everolimus inhibits in-stent neointimal growthAndrew Farb, Michael John, Eduardo Acampado, et al.
JACC. Heart Failure|March 15, 2025
An Innovative Program for Evidence Generation: HFC Perspective on the FDA Total Product Life Cycle Advisory ProgramMona Fiuzat, Kimberly Ferlin, Laura Gottschalk, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Sex-specific Long-term Outcomes of Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial FibrillationHongying Jiang, Qi Zheng, Yun-Ju Cheng, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Clinical Perspective--Early Feasibility Device Medical Studies in the United States: Time for More Than Regulatory ReformDavid R Holmes, Jeff Shuren, Robert Califf, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Circulation|January 24, 2002
Morphological predictors of arterial remodeling in coronary atherosclerosisAllen P Burke, Frank D Kolodgie, Andrew Farb, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|June 9, 2009
Unusual cardiovascular manifestations of sarcoidosis, a report of three cases: coronary artery aneurysm with myocardial infarction, symptomatic mitral valvular disease, and sudden death from ruptured splenic arteryJoel H Barton, Fabio Tavora, Andrew Farb, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 22, 2004
Histology of in-stent restenosis in a transplanted heartPeter N Ruygrok, Andrew Farb, H Arthur Coverdale, et al.
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|March 30, 2016
New technology in electrophysiology: FDA process and perspectiveKimberly A Selzman, Mark Fellman, Andrew Farb, et al.
Circulation|June 26, 2002
Morphological predictors of restenosis after coronary stenting in humansAndrew Farb, Deena K Weber, Frank D Kolodgie, et al.
Circulation|March 12, 2003
Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findingsGiulio Guagliumi, Andrew Farb, Giuseppe Musumeci, et al.
Circulation|October 31, 2002
Oral everolimus inhibits in-stent neointimal growthAndrew Farb, Michael John, Eduardo Acampado, et al.
JACC. Heart Failure|March 15, 2025
An Innovative Program for Evidence Generation: HFC Perspective on the FDA Total Product Life Cycle Advisory ProgramMona Fiuzat, Kimberly Ferlin, Laura Gottschalk, et al.
Journal of the Society for Cardiovascular Angiography & Interventions|August 12, 2024
Sex-specific Long-term Outcomes of Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial FibrillationHongying Jiang, Qi Zheng, Yun-Ju Cheng, et al.
JACC. Cardiovascular Interventions|March 26, 2016
Clinical Perspective--Early Feasibility Device Medical Studies in the United States: Time for More Than Regulatory ReformDavid R Holmes, Jeff Shuren, Robert Califf, et al.
Pageof 10